Hospitalisation and associated costs of gastrointestinal bleeding from primary prevention aspirin use in South Australia: a retrospective case series analysis

Gregory Roberts, Maxwell Baker, Hannah Leiblich, Maryssa Paulose, Matthew Pegoli, Lucas Panagopoulos, Carly Schiller, Vijayaprakash Suppiah

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

We assessed hospitalisations for gastrointestinal bleeding directly related to primary prevention aspirin in lower risk patients for a 6-month period in three South Australian hospitals. Those with related underlying pathology or concurrent causative medication were excluded. Identified patients (n = 22) carried little co-morbidity, 41% received prior proton-pump inhibitors and 68% were aged >70 years. Mean hospital admission cost was $6769 (95% confidence interval $5198–$8340), with projected state and national annual costs of $0.57 and $8.12 million respectively. In light of recent guideline changes, clinicians need to vigorously assess the need for primary prevention aspirin.

Original languageEnglish
Pages (from-to)318-321
Number of pages4
JournalInternal Medicine Journal
Volume52
Issue number2
DOIs
Publication statusPublished - Feb 2022
Externally publishedYes

Keywords

  • adverse drug reaction
  • aspirin
  • cost
  • deprescribing
  • gastrointestinal bleeding
  • primary prevention

Fingerprint

Dive into the research topics of 'Hospitalisation and associated costs of gastrointestinal bleeding from primary prevention aspirin use in South Australia: a retrospective case series analysis'. Together they form a unique fingerprint.

Cite this